Please assess the completion status of the following clinical trial:

Trial Title: Cycling of Sedative Infusions in Critically Ill Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Less than or equal to 18 years of age~* Intubated and mechanically ventilated~* Expected to require continuous infusions of sedatives for at least 48 hours~* Parent or legal guardian available for informed consent~* Males and females of any race are eligible~Exclusion Criteria:~* Less than 72 hours after surgery~* Cyanotic heart disease with unrepaired or palliated right to left intracardiac shunt~* Critical airway (according to PICU Attending)~* Ventilator dependent (including noninvasive) on PICU admission~* Greater than 48 hours of continuous sedation infusion(s)~* Neuromuscular respiratory failure~* Managed by patient controlled analgesia (PCA) or epidural catheter~* Known allergy to any of the study medications (fentanyl or midazolam)~* Family/Medical team have decided not to provide full support (patient treatment considered futile)~* Patient requires ECMO~* Head trauma requiring intracranial pressure monitoring~* Pregnancy~* Following resuscitation from cardiorespiratory arrest whose initial pH is \< 6.9~* ICU Attending judgment that patient should be excluded for safety reasons

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): In this arm Fentanyl and Midazolam was replaced with placebo (normal saline) during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the placebo drug (normal saline). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the placebo drug (normal saline), was started. The switch Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol
- Control Group (Type: ACTIVE_COMPARATOR): In this arm, midazolam and fentanyl were administered during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the control drug (midazolam). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the control drug (fentanyl), was started. The switch to Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).